Literature DB >> 3740510

The extent of metabolism of inhaled anesthetics in humans.

R L Carpenter, E I Eger, B H Johnson, J D Unadkat, L B Sheiner.   

Abstract

To determine the percentage of anesthetic metabolized and to assess the role of metabolism in the total elimination of inhaled anesthetics, the authors administered isoflurane, enflurane, halothane, and methoxyflurane simultaneously, for 2 h, to nine healthy patients. Total anesthetic uptake during the 2 h of washin and total recovery of unchanged anesthetic in exhaled gases during 5 to 9 days of washout were measured, and from these the per cent of anesthetic uptake that was recovered was calculated. Of the isoflurane taken up, 93 +/- 4% (mean +/- SE) was recovered. To compensate for factors other than metabolism that limit complete recovery of unchanged anesthetic, the percentage recovery of each anesthetic was normalized to the percentage recovery of isoflurane (which it was assumed undergoes no metabolism). Deficits in normalized recovery were assumed to be due to metabolism of the anesthetics. The resulting estimates of metabolism of anesthetic taken up were: enflurane 8.5 +/- 1.0%, halothane 46.1 +/- 0.9%, and methoxyflurane 75.3 +/- 1.6%. These results indicate that elimination is primarily via the lungs for isoflurane and enflurane, equally via the lungs and via metabolism for halothane, and primarily via metabolism for methoxyflurane.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740510     DOI: 10.1097/00000542-198608000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  Evaluation of long sampling tubes for remote monitoring by mass spectrometry.

Authors:  J G Lerou; J van Egmond; H H Beneken Kolmer
Journal:  J Clin Monit       Date:  1990-01

Review 2.  Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications.

Authors:  Jean-Xavier Mazoit
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 5.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of the inhalational anaesthetics.

Authors:  O Dale; B R Brown
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis.

Authors:  Peiman Habibollahi; Nastaran Mahboobi; Sara Esmaeili; Saeid Safari; Ali Dabbagh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

8.  Heterogeneity of human adipose blood flow.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2007-01-20

9.  PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics.

Authors:  David G Levitt
Journal:  BMC Anesthesiol       Date:  2002-08-15       Impact factor: 2.217

Review 10.  Medications for analgesia and sedation in the intensive care unit: an overview.

Authors:  Diederik Gommers; Jan Bakker
Journal:  Crit Care       Date:  2008-05-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.